insights_auto
Kwa nini 4547 imepungua kwa 3.39%?
Fahamu zaidichevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
JP¥ 3,700.00
arrow_downward
-3.39%(-130.00) Siku 1
2 Okt, 15:30:00 GMT +9 · JPY
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya 4547...
Fungua
JP¥ 3,810
Juu
JP¥ 3,815
Chini
JP¥ 3,690
Mtaji wa soko
172.21B
Wastani wa kiasi cha mauzo
elfu 66.55
Kiasi cha mauzo ya hisa
elfu 97.50
Gawio
3.24%
Mgawo wa faida wa kila robo mwaka
JP¥ 30
Tarehe ya kutojumuisha gawio
29 Sep 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
10.97
Juu kwa wiki 52
JP¥ 5,040
Chini kwa wiki 52
JP¥ 3,500
EPS
JP¥ 337
Hisa za wawekezaji
46.72M
Idadi ya wafanyakazi
elfu 2
Fungua
JP¥ 3,810
Juu
JP¥ 3,815
Chini
JP¥ 3,690
Mtaji wa soko
172.21B
Wastani wa kiasi cha mauzo
elfu 66.55
Kiasi cha mauzo ya hisa
elfu 97.50
Gawio
3.24%
Mgawo wa faida wa kila robo mwaka
JP¥ 30
Tarehe ya kutojumuisha gawio
29 Sep 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
10.97
Juu kwa wiki 52
JP¥ 5,040
Chini kwa wiki 52
JP¥ 3,500
EPS
JP¥ 337
Hisa za wawekezaji
46.72M
Idadi ya wafanyakazi
elfu 2
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Yahoo Finance
·
dakika 15 zilizopita
Nasdaq, S&P 500, Dow Futures Rise Ahead Of Jobs Report: NKE, META, RKLB, MRNA, SLS, TSLA Stocks In Focus
MarketBeat
·
dakika 28 zilizopita
Biodesix, Inc. (NASDAQ:BDSX) Stock Has Average Target Price of $35.00
Benzinga
·
dakika 34 zilizopita
S&P 500 Edges Higher As Treasury Yields Retreat: Investor Sentiment Declines, Fear & Greed Index Remains
Seeking Alpha
·
saa 1 iliyopita
Inside The September 2026 S&P 500 Momentum Index Reconstitution
Wasifu
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Kuhusu Kissei Pharmaceutical Co Ltd
Afisa Mkuu Mtendaji (CEO)Mutsuo Kanzawa
Wafanyakazielfu 1.79
Lilianzishwa9 Ago 1946
Makao makuuMatsumoto, Mkoa wa Nagano, Japani
Sekta-
Tovutikissei.co.jp